CAR T-Cell Therapy Clears Immune Barriers to Enable Kidney Transplants in Near-Impossible Cases
A novel dual CAR T-cell approach eliminated blocking antibodies in highly sensitized patients, enabling kidney transplants previously considered impossible.
Summary
Researchers at the University of Pennsylvania successfully used dual CAR T-cell therapy to desensitize three kidney transplant patients who had near-zero odds of finding a compatible donor. Published in the New England Journal of Medicine, the phase I trial targeted two immune cell types — CD19 and BCMA — to eliminate the anti-HLA antibodies blocking transplant compatibility. Both patients treated had calculated panel-reactive antibody scores of 99.9% or higher, meaning almost no donor kidneys would work for them. The therapy was well-tolerated and antibody levels have not rebounded. Around 5,000 Americans on the kidney transplant waitlist face this extreme sensitization, leaving them at high risk of dying before a match is found. This approach could offer a transformative solution.
Detailed Summary
For thousands of patients on kidney transplant waiting lists, extreme immune sensitization has meant years of waiting with near-zero chance of finding a compatible donor. A new phase I trial published in the New England Journal of Medicine may change that reality by applying CAR T-cell therapy — best known as a cancer treatment — to erase the immune barriers blocking transplantation.
Researchers at the University of Pennsylvania enrolled patients with calculated panel-reactive antibody scores of 99.9% or higher, meaning their immune systems had pre-existing antibodies against nearly all potential donor kidneys. These patients had previously undergone failed transplants and faced the highest risk of death while waiting. The team administered lymphodepleting chemotherapy followed by infusions of both CD19-targeted and BCMA-targeted CAR T cells, designed to eliminate the plasma cells and B cells producing the problematic anti-HLA antibodies.
The results were striking. The therapy successfully cleared anti-HLA antibodies in both patients treated in the safety cohort, enabling them to proceed to kidney transplantation. Critically, no rebound of donor-specific antibodies has been observed — a persistent problem with older desensitization methods like IVIG, plasmapheresis, and imlifidase. The treatment was also well-tolerated, an important finding given this vulnerable population.
This matters beyond the individual cases. Approximately 5,000 of the 91,000-plus Americans currently awaiting a kidney transplant are highly sensitized, and they disproportionately die or are removed from the list before receiving a transplant. Prior desensitization strategies have shown inconsistent, short-lived efficacy in the most sensitized patients. A durable cellular-level solution would represent a paradigm shift.
Important caveats remain. This is an early-phase safety trial with only two treated patients reported so far. Long-term durability of antibody clearance, transplant outcomes, and broader applicability are still under investigation. Larger controlled trials will be essential before this becomes standard care.
Key Findings
- Dual CAR T-cell therapy targeting CD19 and BCMA cleared near-total anti-HLA antibody sensitization in kidney transplant candidates.
- Both treated patients had 99.9%+ cPRA scores — the hardest-to-match category — and successfully received kidney transplants post-treatment.
- No donor-specific antibody rebound has been observed, overcoming a key failure point of prior desensitization methods.
- Therapy was well-tolerated in this early phase I safety cohort, supporting continued investigation.
- Approximately 5,000 highly sensitized Americans on the transplant waitlist could potentially benefit from this approach.
Methodology
This is a news report summarizing findings from a phase I safety run-in trial published in the New England Journal of Medicine, a top-tier peer-reviewed journal. The evidence is early-stage with only two patients in the reported cohort. The trial is ongoing, and full efficacy data are not yet available.
Study Limitations
Only two patients were reported in this safety cohort, making it impossible to draw broad efficacy or safety conclusions. Long-term transplant outcomes, antibody durability, and immune reconstitution data are still pending. This therapy is experimental and not yet approved or broadly available.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.